New pharmacological interventions for overactive bladder

References

• Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn.21, 167–178 (2002).
   PubMed Web of Science ®Google Scholar
• Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS ONE2, e195 (2007).
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC Study. Eur. Urol.50, 1306–1314 (2006).
   PubMed Web of Science ®Google Scholar
• Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. Epidemiology of incontinence in the county of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J. Clin. Epidemiol.53, 1150–1157 (2000).
   PubMed Web of Science ®Google Scholar
• Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am. J. Manag. Care.6, S599–S606 (2000).
   Google Scholar
• Hannestad YS, Rortveit G, Hunskaar S. Help-seeking and associated factors in female urinary incontinence. The Norwegian EPINCONT Study. Epidemiology of Incontinence in the County of Nord-Trøndelag. Scand. J. Prim. Health Care.20, 102–107 (2002).
   Web of Science ®Google Scholar
• Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br. J. Obstet. Gynaecol.97, 521–526 (1990).
   PubMedGoogle Scholar
• Thüroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol.145(4), 813–816; discussion 816–817 (1991).
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol.104, 988–993 (1997).
   PubMedGoogle Scholar
• Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol.81, 801–810 (1998).
   PubMedGoogle Scholar
• Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc.78, 687–695 (2003).
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin. Proc.76, 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Urol.168, 580–586 (2002).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology62, 237–242 (2003).
   PubMed Web of Science ®Google Scholar
• Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am. J. Obstet. Gynecol.195, 1730–1735 (2006).
   PubMed Web of Science ®Google Scholar
• Davila GW, Sand PK, Gonick CW, Parker RL, Dahl NV. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from MATRIX study. Obstet. Gynecol.107, S76 (2006).
   Google Scholar
• Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int.99, 836–844 (2006).
   PubMed Web of Science ®Google Scholar
• Sand PK, Lucente VR, Parker RL, Goldberg RP, Dahl NV. Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder: results of the MATRIX study. Obstet. Gynecol.107, 76 (2006).
   Google Scholar
• Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J. Urol.23, 263–270 (2005).
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol.172, 1919–1924 (2004).
   PubMed Web of Science ®Google Scholar
• Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol.48, 483–487 (2005).
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol.48, 464–470 (2005).
   PubMed Web of Science ®Google Scholar
• Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur. Urol.52(4), 1195–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Nelson CP, Gupta P, Napier CM, Nahorski SR, Challiss RA. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J. Pharmacol. Exp. Ther.310, 1255–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol.45, 420–429; discussion 429 (2004).
   PubMed Web of Science ®Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol.23, 248–252 (2005).
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int.98, 1025–1032 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol.173, 493–498 (2005).
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol.50, 317–326 (2006).
   PubMed Web of Science ®Google Scholar
• Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet. Gynecol.104, 511–519 (2004).
   PubMed Web of Science ®Google Scholar
• Steers WD, Herschorn S, Kreder KJ et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int.100, 337–345 (2007).
   PubMed Web of Science ®Google Scholar
• Duckett JR, Vella M, Kavalakuntla G, Basu M. Tolerability and efficacy of duloxetine in a nontrial situation. BJOG114, 543–547 (2007).
   PubMed Web of Science ®Google Scholar
• Bent AE, Gousse AE, Hendrix SL et al. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourol. Urodyn. (2007) (Epub ahead of print).
   Google Scholar
• Stöhrer M, Mürtz G, Kramer G et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, double-blind, multicenter clinical study. Eur. Urol.51, 235–242 (2007).
   Google Scholar
• Abrams P, Cardozo L, Chapple C et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J. Urol.13, 692–698 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int.100, 579–587 (2007).
   PubMed Web of Science ®Google Scholar
• Jünemann KP, Hessdörfer E, Unamba-Oparah I et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol. Int.77, 334–339 (2006).
   PubMed Web of Science ®Google Scholar
• Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br. J. Urol.54, 252–255 (1982).
   PubMedGoogle Scholar
• Lose G, Lalos O, Freeman RM, van errebroeck P, Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am. J. Obstet. Gynecol.189, 1106–1113 (2003).
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Rezapour M, Cortesse , Thüroff J, Riis A, Nørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur. Urol.52, 221–229 (2007).
   PubMed Web of Science ®Google Scholar
• Zahariou A, Karamouti M, Karagiannis G, Papaioannou P. Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int. Urol. Nephrol. (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Lose G, Mattiasson A, Walter S et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J. Urol.172, 1021–1025 (2004).
   Google Scholar
• Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol. Urodyn.25, 105–109 (2006).
   PubMed Web of Science ®Google Scholar
• Bae JH, Oh MM, Shim KS et al. The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study. J. Urol.178, 200–203 (2007).
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int.93, 996–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Hashim H, Malmberg L, Graugaard-Jensen C, Abrams P. Antidiuresis in the treatment of overactive bladder syndrome. Neurourol. Urodyn.25, 618–619 (2006).
   Web of Science ®Google Scholar
• Duthie J, Wilson D, Herbison G. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst. Rev.3, CD005493 (2007).
   Google Scholar
• Reitz A, Denys P, Fermanian C, Schurch , Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur. Urol.52(6), 1729–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Darblade B, Behr-Roussel D, Oger S et al. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology68, 442–448 (2006).
   PubMed Web of Science ®Google Scholar
• Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur. Urol.49, 879–886 (2006).
   PubMed Web of Science ®Google Scholar